PubMed · 2014 · 73 citations · 66 references
Life SciencesMedicinal ChemistryOncologyDrug DesignDrug DiscoveryStructural BiologyLigand BindingProtein BindingProtein StructureProtein-ligand BindingProtein-ligand InteractionsScaffold ProteinsAmino AcidsBindersLigand Binding AffinityMonoclonal Antibodies In CancerMultivalent Ligand BindingMultivalent Protein BindingProtein-based Imaging AgentsProtein-based Scaffolds
In order to overcome limitations of monoclonal antibodies, new protein-based scaffolds have been designed and evaluated pre-clinically, and some of them are in clinical studies for the treatment of cancer. These entities can be placed into two categories: scaffolds which bind ligands via amino acids in exposed loops and those in which ligand binding is mediated by amino acids in secondary structures, such as β-sheet modules. Accordingly, we discuss adnectins, lipocalins, Kunitz domain-based binders, avimers, knottins, fynomers, atrimers and cytotoxic T-lymphocyte associated protein-4 (CTLA4)-based binders which fall into the first category, while darpins, affibodies, affilins and armadillo repeat protein-based scaffolds are members of the second category. In addition, we also discuss the new molecular entities as imaging tools and outline their unique characteristics in the context of multimeric and multivalent binding.
66
Enhancement of Antitumor Immunity by CTLA-4 Blockade
Dana R. Leach, Matthew F. Krummel, James P. Allison · Science · 1996 · 3.9K citations
Life Sciences, Immunology, Oncology +17
Identification of a Ten-Amino Acid Proline-Rich SH3 Binding Site
Ruibao Ren, Bruce J. Mayer, Piera Cicchetti et al. · Science · 1993 · 1.2K citations
Potent enzyme inhibitors derived from dromedary heavy‐chain antibodies
Marc Lauwereys · The EMBO Journal · 1998 · 487 citations · Full text